Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice.

Published

Journal Article

The human medulloblastoma cell line TE-671 was grown s.c. and intracranially in athymic nude mice. Tumor-bearing animals treated with chemotherapeutic agents or radiation were compared to untreated tumor-bearing controls. Tumors growing s.c. were sensitive to cyclophosphamide and vincristine with growth delays in duplicate trials of 15.8/16.5 and 12.9/15.0 days, respectively. These tumors were minimally responsive to the 2,5-bis(1-aziridinyl-3,6-dioxodiethyl ester of 1,4-cyclohexadiene-1,4-dicarbamic acid (NSC 182986) and cis-diamminedichloroplatinum II and unresponsive to methotrexate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine (NSC 351521), 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC 409962), and procarbazine. Radiation therapy with 2500 or 1500 rads as a single fraction produced a marked response, with growth delays of 39.5 and 21.1 days, respectively. Cyclophosphamide produced a significant (p less than 0.0005) increase in the median survival of mice with intracranial tumors. Vincristine produced a minimal increase in the median survival while no response was seen to the 2,5-bis(1-aziridinyl-3,6-dioxodiethyl ester of (1,4-cyclohexadiene-1,4-dicarbamic acid at the dose level and schedule tested. This model system will allow further analysis of the therapeutic sensitivity of human medulloblastoma to other agents or combined-modality regimens.

Full Text

Duke Authors

Cited Authors

  • Friedman, HS; Schold, SC; Varia, M; Bigner, DD

Published Date

  • July 1, 1983

Published In

Volume / Issue

  • 43 / 7

Start / End Page

  • 3088 - 3093

PubMed ID

  • 6850617

Pubmed Central ID

  • 6850617

International Standard Serial Number (ISSN)

  • 0008-5472

Language

  • eng

Conference Location

  • United States